Navigation Links
NeuroDerm Announces Enrollment in a Phase 2 Study of ND0612, a Continuous Levodopa/Carbidopa Drug for the Treatment of Parkinson's Disease
Date:4/15/2013

NESS ZIONA, Israel, April 15, 2013 /PRNewswire/ --

NeuroDerm, Ltd. announced today that enrollment of patients is ongoing in its Phase IIa clinical trial of ND0612, a novel drug formulation for the treatment of Parkinson's disease. ND0612 is a proprietary levodopa/carbidopa liquid formula under development for continuous sub-cutaneous administration through a patch pump.  It is designed to provide steady levodopa blood levels in Parkinson's disease.

In previous phase I studies, ND0612 was shown to be safe and tolerable and reached steady state, clinically meaningful levodopa concentrations for the first time in man.  Furthermore, steady state levodopa concentrations were maintained in a practical manner during both day and night. The current Phase II double-blind, randomized placebo controlled study in Parkinson's disease patients will assess ND0612 for safety and tolerability as well as for levodopa and carbidopa steady state plasma levels.

"Following its success in phase I trials, ND0612 is now entering trials in patients. An important objective of this study will be to find out what steady state levodopa concentrations can be reached in patients. In healthy volunteers, ND0612 reached day and night steady state levodopa levels, the elusive holy grail of Parkinson's levodopa therapy, in a conveniently administered drug that should be available to all PD patients. Moreover, ND0612 bypasses the gastrointestinal tract and should be little influenced by intestinal absorption or oral ingestion of food or drugs. This trial marks a landmark in the development of ND0612, a novel levodopa drug that could become a breakthrough treatment option in Parkinson's Diseases."

About Parkinson's Disease

Parkinson's disease affects approximately 6M patients in the world. It is caused by decreasing dopamine signaling in the brain as dopaminergic brain cells die off. Levodopa is the "Gold
'/>"/>

SOURCE NeuroDerm Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer
2. Probiotic Action Announces New Insight on Why Acne is a Problem for First World Citizens and Offers Advice on Treatments
3. Vestiage Announces Key Partners for Launch of Monterey Bay Nutraceuticals Anti-Aging Wellness Products
4. Probiotic Action Announces A New Natural Alternative to Expensive and harmful Acne Treatments
5. Rigaku Announces New EDXRF Method for Elemental Analysis in Gold Processing
6. ?The MedZilla.com Employment Report for April, 2013: Unemployment Rate Drops as Obama Announces Major Bio-Tech Research Initiative
7. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
8. Vestiage Announces Filing of Disclosure Statement with Exchange
9. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
10. BioRestorative Therapies Announces Chairman of Its Scientific Advisory Board to Speak at Vatican
11. Probiotic Action Announces New Edible Probiotic Trend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... (PRWEB) October 19, 2014 The Asian ... in Asian with analysis and forecast of revenue. The ... grow to around $463.9 million by 2018, at a ... Browse through the TOC of the Asian Automatic patient ... analysis provided. This also provides a glimpse of the ...
(Date:10/19/2014)... 19, 2014 According to market ... Points; WLAN Controllers; Wireless gateways)]- Global Advancements, Forecasts ... the global Outdoor Wi-Fi market with analysis and ... MarketsandMarkets also identifies the drivers and the restrains ... trends, opportunities and challenges. , Browse 65 market ...
(Date:10/18/2014)... The Asia-Pacific hardware encryption display market report defines ... and forecast of revenue. This market was valued $5,154.0 ... million by 2018, at a CAGR of 58.4% from ... the Asia-Pacific hardware encryption market report, to get an ... a glimpse of the segmentation of the market, and ...
(Date:10/18/2014)... 2014 The report " Cloud ... Text; Web; Speech; Machine; Video; Predictive Analytics: Global ... Forecasts & Analysis (2013 - 2018) ", defines ... various sub segments with an in-depth analysis and ... the factors driving this market, various restraints, and ...
Breaking Biology Technology:The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 2The Asian Automatic patient billing market is estimated to grow to around $463.9 million by 2018 - New Report by MicroMarket Monitor 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 2Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 3Outdoor Wi-Fi Market (by Access Points, WLAN Controllers, Wireless gateways) Expected to Cross $37.2 Billion by 2018 - New Report by MarketsandMarkets 4The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 2The Asia-Pacific hardware encryption display market is expected to reach $51,362.6 million by 2018 - New Report by MicroMarket Monitor 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 2Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 3Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 4Cloud Analytics Market (by Cloud Business Intelligence & Predictive Analytics) Expected to Cross $16.52 Billion by 2018 - New Report by MarketsandMarkets 5
... LA JOLLA, Calif., March 18 TorreyPines Therapeutics,Inc. ... initiated a Phase II study of,NGX267, a muscarinic ... to Sjogren,s syndrome., The company is conducting ... square design to evaluate,the safety, tolerability and efficacy ...
... NEOG ) announces the following Webcast:, What: Neogen ... EDT, Where: http://www.videonewswire.com/event.asp?id=46587 , How: ... the address above., ... are unable to participate during the live webcast, the call will,be archived ...
... - Oncolytics Biotech Inc.,(TSX: ONC, NASDAQ: ONCY) ("Oncolytics") ... 7,344,711 entitled "Use of Adenoviruses Mutated in the,VA ... of treating,cancer using adenoviruses that are modified to ... Ras pathway., "This patent expands our adenovirus ...
Cached Biology Technology:TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4Oncolytics Biotech Inc. Announces Issuance of 26th U.S. Patent 2
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
(Date:10/15/2014)... Life, is a non-traditional biophysics textbook and it describes ... a journey of discovery into biological systems and provides ... regulation. It is about how our genes make proteins ... billions of cells in an organism. It quantifies the ... which can be found on both large and small ...
(Date:10/15/2014)... is spreading rapidly and to an unexpected extent. The ... past and the virus shows a new disease dynamic ... For this reason, the German National Academy of Sciences ... Engineering, and the Union of the German Academies of ... Ebola epidemic today. , In the statement the academies ...
Breaking Biology News(10 mins):Sandata Announces Case Study with Quality Care Services, Inc. 2New book about life as seen from physics 2Academies call for consequences from the Ebola virus epidemic 2Academies call for consequences from the Ebola virus epidemic 3Academies call for consequences from the Ebola virus epidemic 4Academies call for consequences from the Ebola virus epidemic 5
... nutrient world The budding yeast, Saccharomyces ... cellular processes, with the functions of many proteins important ... human biology having first been discovered in yeast. ... developed a sophisticated assay to track cell growth at ...
... 17, 2013) The New York Genome Center (NYGC) ... (NYSCF) has become an Associate Member, joining NYGC,s growing ... together in new ways to utilize genomic data for ... at the NYSCF working with the genomic scientists at ...
... From Promise to Practice is the title and the ... at Mayo Clinic, Sept. 30-Oct. 2. Physicians from more ... in Minnesota to hear and learn about the latest ... move these discoveries into the medical practice. "Our ...
Cached Biology News:Recent highlights in Molecular Biology and Evolution 2Recent highlights in Molecular Biology and Evolution 3New York Genome Center announces the New York Stem Cell Foundation as an Associate Member 2New York Genome Center announces the New York Stem Cell Foundation as an Associate Member 3Mayo Clinic hosts NIH genomics director at Individualizing Medicine Conference 2
... Antibody to Human Cytokeratin TYPE II ... II) keratins. Including epidermal cell keratin of ... 65kD and 67kD. Broad keratin reactivity is ... cornea. Immunogen: Human ...
BD BioCoat Fibronectin 150 mm Culture Dishes...
... new product number, created to easily match ... yet, please order under the old Sigma-Aldrich ... assistance. ID clarifier: tissue-culture treated ... cm 2 D H 245 ...
... Novagens PhageMaker System is optimized for maximum ... ligated with any bacteriophage l vector. Using a ... > 10^7 pfu/g arms (> 4 x 10^8 ... This one-tube system is extremely easy to use; ...
Biology Products: